Orion Entered into an Agreement with Jemincare to Develop & Commercialize JMKX000623 for the Treatment of Pain

Published: May 6, 2022 | Tags: Orion, Jemincare, JMKX000623, Pain

Amylyx Publishes Results of AMX0035 in P-II (CENTAUR) Trial for the Treatment of Amyotrophic Lateral Sclerosis in Muscle & Nerve

Published: May 6, 2022 | Tags: Amylyx, AMX0035, P-II, CENTAUR Trial, Amyotrophic Lateral Sclerosis, Muscle, Nerve

Palisade Bio and Newsoara’s LB1148 Receive NMPA’s Clearance to Initiate P-III Trial to Improve Bowel Function After Abdominal Surgery

Published: May 6, 2022 | Tags: Palisade Bio, Newsoara, LB1148, NMPA, Clearance, P-III Trial, Bowel Function, Abdominal Surgery

Zai Lab Partner argenx Report Results of Vyvgart (efgartigimod alfa-fcab) P-III (ADVANCE) Trial for Primary Immune Thrombocytopenia

Published: May 6, 2022 | Tags: Zai Lab, argenx, Vyvgart, efgartigimod alfa-fcab, P-III, ADVANCE Trial, Primary Immune Thrombocytopenia

Scilex Presents Results of Semdexa (SP-102) in P-III (SEMDEXA) Trial for the Treatment of Sciatica Pain Management at ASIPP 2022

Published: May 6, 2022 | Tags: Scilex Presents Results of Semdexa (SP-102) in P-III (SEMDEXA) Trial for the Treatment of Sciatica Pain Management at ASIPP 2022

Biogen Entered into a License Agreement with MedRhythms to Develop and Commercialize MR-004 for the Treatment of Gait Deficits in Multiple Sclerosis

Published: May 6, 2022 | Tags: Biogen, MedRhythms, MR-004, Gait Deficits, Multiple Sclerosis

AstraZeneca’s Farxiga (dapagliflozin) Meet its Primary Endpoints in the P-III (DELIVER) Trial for Heart Failure with a Preserved Ejection Fraction

Published: May 5, 2022 | Tags: AstraZeneca, Farxiga, P-III, DELIVER Trial, Heart Failure, Preserved Ejection Fraction

Byondis Entered into a Multiple Agreement with medac to Commercialize Trastuzumab Duocarmazine (SYD985) for the Treatment of Cancer

Published: May 5, 2022 | Tags: Byondis, medac, Trastuzumab Duocarmazine, SYD985, Cancer

Novartis Updated Exploratory OS Analysis of Kisqali (ribociclib) in P-III (MONALEESA-3) Trial for the Treatment of HR+/HER2- Advanced Breast Cancer

Published: May 5, 2022 | Tags: Novartis, Kisqali, ribociclib, P-III, MONALEESA-3 Trial, HR+, HER2-, Breast Cancer

Incyte’s Jakavi (ruxolitinib) Receives EC’s Approval as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease

Published: May 5, 2022 | Tags: Incyte, Jakavi, ruxolitinib, EC, Approval, Post-Steroid, Acute, Chronic, Graft-Versus-Host Disease

Jazz Entered into an Exclusive License Agreement with Sumitomo Pharma to Develop and Commercialize DSP-0187 for the Treatment of Sleep Disorders

Published: May 5, 2022 | Tags: Jazz, Sumitomo Pharma, DSP-0187, Sleep Disorder

Amphista Signs a License Agreement with BMS to Discover & Develop Targeted Protein Degradation Therapies Using Eclipsys TPD Platform

Published: May 5, 2022 | Tags: Amphista, BMS, Protein Degradation Therapies

BeiGene’s Blincyto (blinatumomab) Receives the NMPA’s Approval for Pediatric Patients with Relapsed or Refractory B-Cell Precursor ALL

Published: May 4, 2022 | Tags: BeiGene, Blincyto, blinatumomab, NMPA, Approval, Pediatric Patients,  Relapsed or Refractory, B-Cell Precursor ALL

The US FDA Issued Complete Response Letter to Hutchmed’s Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

Published: May 4, 2022 | Tags: US, FDA, Complete Response Letter, Hutchmed, Surufatinib, Advanced Neuroendocrine Tumors

Horizon Reports Results of HZN-4920 in P-II Study for Rheumatoid Arthritis

Published: May 4, 2022 | Tags: Horizon, HZN-4920, P-II, Rheumatoid Arthritis

iSono Health’s ATUSA System Receives the US FDA’s Approval as the World’s First Automated and Wearable 3D Breast Ultrasound

Published: May 4, 2022 | Tags: iSono Health, ATUSA, US FDA, Breast Imaging

Hepion Collaborates with HepQuant for P-IIb Study of Rencofilstat (CRV431) in NASH

Published: May 4, 2022 | Tags: Hepion, HepQuant, P-IIb,  Rencofilstat, CRV431, NASH

Vertex Reports the FDA’s Clinical Hold on P-I/II Study of VX-880 for the Treatment of Type 1 Diabetes

Published: May 4, 2022 | Tags: Vertex, FDA, Clinical Hold, P-I/II Study, VX-880, Type 1 Diabetes

Ipsen’s Cabometyx Receives EC’s Approval as a 2L treatment for Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Published: May 3, 2022 | Tags: Ipsen, Cabometyx, EC, Approval, Radioactive, Iodine-Refractory, Differentiated Thyroid Cancer

Genesis Entered into a Collaboration with Lilly to Discover Novel Therapies for up to Five Targets

Published: May 3, 2022 | Tags: Genesis, Lilly, Novel Therapies, AI Drug Discovery Platform

Denali Partner Sanofi Reports the Patient Dosing in P-II (HIMALAYA) Study of SAR443820 for the Treatment of Amyotrophic Lateral Sclerosis

Published: May 3, 2022 | Tags: Denali, Sanofi, P-II, HIMALAYA Study, SAR443820, Amyotrophic Lateral Sclerosis

Apellis Presents 18-Month Results of Pegcetacoplan in P-III (DERBY) and (OAKS) Studies for the Treatment of Geographic Atrophy at ARVO 2022

Published: May 3, 2022 | Tags: Apellis, Pegcetacoplan, P-III, DERBY, OAKS Studies, Geographic Atrophy, ARVO, 2022

UCB Publishes Results of Fintepla (fenfluramine) in the P-III Trial for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome in JAMA Neurology

Published: May 3, 2022 | Tags: UCB, Fintepla, fenfluramine, P-III Trial, Seizures, Lennox-Gastaut Syndrome, JAMA Neurology

Gilead Entered into a Research Collaboration with Dragonfly to Develop Natural Killer Cell Engagers for Oncology and Inflammation Indications

Published: May 3, 2022 | Tags: Gilead, Dragonfly, Natural Killer Cell Engagers, Oncology, Inflammation Indications

Sage and Biogen Initiate Rolling Submission of NDA to US FDA for Zuranolone to Treat Major Depressive Disorder

Published: May 2, 2022 | Tags: Sage Therapeutics, Biogen, NDA, US FDA, Zuranolone, Major Depressive Disorder

CytoSorbents Reports the First Patient Enrollment of DrugSorb-ATR Antithrombotic Removal System in the (STAR-D) Trial During Cardiac Surgery

Published: May 2, 2022 | Tags: CytoSorbents, DrugSorb-ATR Antithrombotic Removal System, STAR-D Trial, Cardiac Surgery

Abbott Reports Results of TactiCath SE in (PERSIST-END) Study for the Treatment of Persistent Atrial Fibrillation

Published: May 2, 2022 | Tags: Abbott, TactiCath SE, PERSIST-END Study, Persistent Atrial Fibrillation

Horizon’s Uplizna (inebilizumab) Receives EC’s Approval for the Treatment of Neuromyelitis Optica Spectrum Disorder

Published: May 2, 2022 | Tags: Horizon, Uplizna, inebilizumab, EC, Approval, Neuromyelitis Optica Spectrum Disorder

Merck’s Keytruda (pembrolizumab) Receives EC’s Approval for MSI-H or dMMR Tumors in Five Different Types of Cancer

Published: May 2, 2022 | Tags: Merck, Keytruda, pembrolizumab, EC, Approval, MSI-H, dMMR Tumors, Cancer

Ionova Entered into a Clinical Trial Collaboration with MSD to Evaluate INV-1120 + Keytruda (pembrolizumab) for Advanced Solid Tumors

Published: May 2, 2022 | Tags: Ionova, MSD, INV-1120, Keytruda (pembrolizumab) for Advanced Solid Tumors

Related Post: PharmaShots Weekly Snapshots (April 25-29, 2022)